AMG-47a
Based on 3 publication(s) in Google Scholar
AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC50=0.2 nM). AMG-47a inhibits VEGF2, p38α, p38α, Jak3, MLR, and IL-2 with IC50 of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as TGF-β, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.19%
- CAS. Nr.: 882663-88-9
- Formel: C29H28F3N5O2
- Molecular Weight:535.56
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) AMG-47a
More-
WB
Alle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
IC50: 0.2 nM (Lck), 1 nM (VEGF2), 3 nM (p38α), 72 nM (Jak3), 30 nM (MLR), 21 nM (IL-2)[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| T-cell | IC50 |
21 nM
Compound: 47
|
Inhibition of anti CD3/CD28-induced IL2 secretion in human T cells
Inhibition of anti CD3/CD28-induced IL2 secretion in human T cells
|
[PMID: 16970394] |
| T-cell | IC50 |
30 nM
Compound: 47
|
Inhibition of human T cell proliferation by mixed lymphocyte reaction
Inhibition of human T cell proliferation by mixed lymphocyte reaction
|
[PMID: 16970394] |
AMG-47a (100 nM-5 μM; 48 h) significantly reduces the level of EGFP-KRASG12V protein in HeLa cells, without significant effect on EGFP protein[1].
AMG-47a (0.2 nM; 5 min) effectively inhibits the phosphorylation of Lck in CD4+ T cells, wtih comparable function to that of Nintedanib (HY-50904)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 882663-88-9
-
Appearance Solid
-
Molecular Weight 535.56
-
Formel C29H28F3N5O2
-
Color Light yellow to yellow
-
SMILES
O=C(NC1=CC=CC(C(F)(F)F)=C1)C2=CC=C(C)C(C3=CC4=CN=C(NCCN5CCOCC5)N=C4C=C3)=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL. [Abstract]2022 Apr 1;13(4):291. PMID: 35365636 -
Oncogene
2018 Aug;37(31):4226-4238. PMID: 29717260
AMG-47a purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Aug;37(31):4226-4238. [Abstract]
AMG-47 results in decreased ERK phosphorylation.
-
Arch Pharm (Weinheim)
Discovery of potent CSK inhibitors through integrated virtual screening and molecular dynamic simulation. [Abstract]2024 Sep;357(9):e2400066. PMID: 38809025
Lösungsmittel & Löslichkeit
DMSO : ≥ 34 mg/mL (63.48 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Carver J, et al. A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. PLoS One. 2014 Aug 5;9(8):e103836. [Content Brief]
[2]. DiMauro EF, et al. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. [Content Brief]
[3]. Kagawa K, et al. The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-β production in regulatory T-cells. PLoS One. 2022 Oct 27;17(10):e0275987. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8672 mL | 9.3360 mL | 18.6720 mL | 46.6801 mL |
| 5 mM | 0.3734 mL | 1.8672 mL | 3.7344 mL | 9.3360 mL | |
| 10 mM | 0.1867 mL | 0.9336 mL | 1.8672 mL | 4.6680 mL | |
| 15 mM | 0.1245 mL | 0.6224 mL | 1.2448 mL | 3.1120 mL | |
| 20 mM | 0.0934 mL | 0.4668 mL | 0.9336 mL | 2.3340 mL | |
| 25 mM | 0.0747 mL | 0.3734 mL | 0.7469 mL | 1.8672 mL | |
| 30 mM | 0.0622 mL | 0.3112 mL | 0.6224 mL | 1.5560 mL | |
| 40 mM | 0.0467 mL | 0.2334 mL | 0.4668 mL | 1.1670 mL | |
| 50 mM | 0.0373 mL | 0.1867 mL | 0.3734 mL | 0.9336 mL | |
| 60 mM | 0.0311 mL | 0.1556 mL | 0.3112 mL | 0.7780 mL |